Previous close | 38.80 |
Open | 39.01 |
Bid | 38.26 x 100 |
Ask | 38.51 x 100 |
Day's range | 38.01 - 39.39 |
52-week range | 27.99 - 50.99 |
Volume | |
Avg. volume | 352,570 |
Market cap | 2.9B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Phase 3 epilepsy program continues to progress with anticipated completion of patient enrollment in X-TOLE2 in late 2024 to early 2025 Successful “end-of-Phase 2” interactions with FDA in MDD; Phase 3 program on track to initiate in the second half of the year Azetukalner now the international nonproprietary name (INN) and United States adopted name (USAN) for XEN1101 Conference call at 4:30 pm ET today VANCOUVER, British Columbia, May 09, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nas
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the BofA Securities Health Care Conference 2024 taking place May 14-16, 2024 in Las Vegas, NV. Fireside Chat Presentation Details:Date:Wednesday, May 15, 2024Time:3:40 pm Pacific Time (6:40 pm Eastern Time)Webcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerSherry A
VANCOUVER, British Columbia, May 07, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, today announced that the company will present at the 2024 RBC Capital Markets Global Healthcare Conference taking place May 14-15, 2024 in New York, NY. Fireside Chat Presentation Details: Date:Tuesday, May 14, 2024Time:3:35 pm Eastern TimeWebcast:Register herePresenters:Ian Mortimer, President and Chief Executive OfficerSherry Aulin, Chief Fin